Scienmag

NOVEMBER 9, 2020

Credit: Insilico Tuesday, November 10, 2020 (9AM Beijing) – Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, today announced that it entered into a multi-target drug discovery agreement with Janssen Pharmaceutica N.V.

Drugs 53

Drugs Clinical Trials Clinical Trials Medicine 53

Scienmag

OCTOBER 21, 2020

Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.

Drugs 73

Drugs Research Clinical Trials Clinical Trials 73

Scienmag

DECEMBER 23, 2020

The Phase 3 clinical trial showed that the drug, called CC-486, significantly improved survival in older patients, over the age of 55, with AML A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement […].

Trials 40

Trials Clinical Trials Clinical Trials Drugs 40

Scienmag

OCTOBER 1, 2020

Final results of nine-year survival outcomes from NeoALTTO BIG-06 trial for patients with HER2-positive breast cancer Final analysis of results from a randomised clinical trial of lapatinib and trastuzumab given before surgery in patients with early HER2-positive breast cancer has found that women who had no signs of residual disease after treatment (..)

Clinical Trials 42

Clinical Trials Clinical Trials Trials Drugs 42